Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Martin S. Maron, Ahmad Masri, Michael E. Nassif, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 20, pp. 1849-1861
Closed Access | Times Cited: 99

Showing 1-25 of 99 citing articles:

Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice
Luís R. Lopes, Carolyn Y Ho, Perry Elliott
European Heart Journal (2024) Vol. 45, Iss. 30, pp. 2727-2734
Open Access | Times Cited: 20
Artificial intelligence-guided detection of under-recognised cardiomyopathies on point-of-care cardiac ultrasonography: a multicentre study
Evangelos K. Oikonomou, Akhil Vaid, Gregory Holste, et al.
The Lancet Digital Health (2025) Vol. 7, Iss. 2, pp. e113-e123
Closed Access | Times Cited: 4
Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years
Daniele Massera, Mark V. Sherrid, Elizabeth Adlestein, et al.
Journal of the American Heart Association (2025)
Open Access | Times Cited: 2
Association of neighborhood median income to outcomes in hypertrophic cardiomyopathy
Raoul Wadhwa, Rohan M. Desai, Shilpa Rao, et al.
Progress in Cardiovascular Diseases (2025)
Closed Access | Times Cited: 2
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy
Ahmad Masri, Rhanderson Cardoso, Theodore P. Abraham, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 19, pp. 1806-1817
Open Access | Times Cited: 13
Hypertrophic cardiomyopathy management: a systematic review of the clinical practice guidelines and recommendations
Mihir M. Sanghvi, Eamon Dhall, C. Anwar A. Chahal, et al.
European Heart Journal - Quality of Care and Clinical Outcomes (2025)
Closed Access | Times Cited: 1
Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten
Donghong Xu, Justin D. Lutz, Punag Divanji, et al.
Clinical Pharmacokinetics (2025)
Open Access | Times Cited: 1
Comparable outcomes in single versus multiple septal branches alcohol ablation for obstructive hypertrophic cardiomyopathy
Josef Veselka, Eva Hansvenclová, Klára Hulíková Tesárková, et al.
International Journal of Cardiology (2025), pp. 133145-133145
Closed Access | Times Cited: 1
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM
Caroline Coats, Ahmad Masri, Michael E. Nassif, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 15
Open Access | Times Cited: 7
Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy
Milind Y. Desai, Eugene Braunwald
Med (2024) Vol. 5, Iss. 7, pp. 655-659
Closed Access | Times Cited: 6
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy
Charles F Sherrod, Sara Saberi, Michael E. Nassif, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 19, pp. 1773-1785
Open Access | Times Cited: 6
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy
Martin S. Maron, Ahmad Masri, Michael E. Nassif, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 19, pp. 1821-1831
Open Access | Times Cited: 6
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sheila M. Hegde, Brian Claggett, Xiaowen Wang, et al.
Journal of the American College of Cardiology (2024)
Open Access | Times Cited: 5
Aficamten and Cardiopulmonary Exercise Test Performance
Matthew M.Y. Lee, Ahmad Masri, Michael E. Nassif, et al.
JAMA Cardiology (2024)
Closed Access | Times Cited: 5
Canadian Cardiovascular Society Clinical Practice Update on Contemporary Management of the Patient With Hypertrophic Cardiomyopathy
Andrew M. Crean, Arnon Adler, Laura Arbour, et al.
Canadian Journal of Cardiology (2024) Vol. 40, Iss. 9, pp. 1503-1523
Open Access | Times Cited: 4
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor
Rajaa Sukhun, Peadar Cremin, Donghong Xu, et al.
Xenobiotica (2024) Vol. 54, Iss. 9, pp. 686-700
Closed Access | Times Cited: 4
Atrial Fibrillation in Hypertrophic Cardiomyopathy
Adaya Weissler‐Snir, Sara Saberi, Timothy C. Wong, et al.
JACC Advances (2024) Vol. 3, Iss. 9, pp. 101210-101210
Open Access | Times Cited: 4
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM
Ahmad Masri, Lubna Choudhury, Roberto Barriales‐Villa, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 19, pp. 1839-1849
Open Access | Times Cited: 4
Goal-Directed Versus Self-Directed Valsalva Maneuver in Patients With Hypertrophic Cardiomyopathy on Cardiac Myosin Inhibitor Therapy
Aakash Bavishi, Marc P. M. Soutar, Margaret Kurnides, et al.
JACC Advances (2025) Vol. 4, Iss. 2, pp. 101531-101531
Open Access
Hypertrophic Cardiomyopathy: New Clinical and Therapeutic Perspectives of an “Old” Genetic Myocardial Disease
Chiara Calore, Mario Mangia, Cristina Basso, et al.
Genes (2025) Vol. 16, Iss. 1, pp. 74-74
Open Access
The JCF 2024 Year-In-Review
Jennifer Maning, Anuradha Lala, Robert J. Mentz
Journal of Cardiac Failure (2025) Vol. 31, Iss. 1, pp. 1-3
Closed Access
Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials
Anas Abunada, Madiha Shah, Ashwani Kumar, et al.
Frontiers in Cardiovascular Medicine (2025) Vol. 11
Open Access
The Efficacy and Safety of Cardiac Myosin Inhibitors Versus Placebo in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials
Chidubem Ezenna, Mrinal Murali Krishna, Meghna Joseph, et al.
The American Journal of Cardiology (2025)
Closed Access
Outcome Measures for Randomised Clinical Trials and Multicentre Observational Studies of Cardiovascular Diseases Published in Major Clinical Journals: Systematic Review and Evidence Mapping
Asad Bhatty, Chris Wilkinson, Suleman Aktaa, et al.
(2025)
Closed Access
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy
Pablo García‐Pavía, Ozlem Bilen, Melissa Burroughs, et al.
JACC Heart Failure (2025) Vol. 13, Iss. 2, pp. 346-357
Open Access
Page 1 - Next Page

Scroll to top